Navigation Links
Ranbaxy Launches Authorized Generic Version of Rocaltrol(R)
Date:9/2/2009

PRINCETON, N.J., Sept. 2 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with Validus Pharmaceuticals LLC (Validus) to market and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral liquid formulation. Overall market sales for calcitriol softgel capsules and oral liquid were $70 million (IMS - MAT: June 2009).

Rocaltrol(R) is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure not yet on dialysis, and in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. Rocaltrol(R) is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypo-parathyroidism.

"Ranbaxy was very pleased to be selected by Validus as their distribution partner for an authorized generic version of Rocaltrol(R). This product represents an excellent commercial opportunity for Ranbaxy which will increase our visibility and presence in the U.S. healthcare system. We look forward to a long and prosperous partnership with Validus," said Jim Meehan, Vice President of Sales and Distribution for RPI.

Ranbaxy will launch product immediately to all classes of trade in the U.S. market, and expects to be the only generic company offering all forms and strengths of generic Rocaltrol(R).

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. Ranbaxy is a subsidiary of Daiichi Sankyo Company, Ltd.

Validus Pharmaceuticals LLC is focused on acquiring, developing and marketing effective, underutilized branded products in specialty therapeutic areas. During the past three years, the company has successfully acquired four products with specific therapeutic advantages that provide a current revenue stream. Validus seeks to acquire drug assets that are approved by the FDA and have well defined and accepted clinical utility relevant to today's practice of medicine. Validus is a portfolio company of Wood Creek Capital Management, LLC, a registered investment advisor that is focused on alternative investments. For more information about Validus Pharmaceuticals, visit www.validuspharma.com.

    CONTACTS: Charles M. Caprariello
              Vice President, Corporate Communications
              Ranbaxy Inc.
              (609) 720-5615

              Edwige Buteau
              RF Binder Partners Inc.
              (212) 994-7517

              Andrea Pavone
              RF Binder Partners Inc.
              (212) 994-7568


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy Receives Final Approval to Manufacture and Market Glycopyrrolate Tablets
2. Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets
3. Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets
4. Press Statement Issued by Ranbaxy Laboratories Limited
5. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
6. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
7. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
8. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
9. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
10. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
11. Ranbaxy Receives Tentative Approval For Valsartan Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, ... stem (iPS) cells and other difficult to transfect cells, announces its launch of ... PluriQ™ G9™ Gene Editing System is a complete system for culturing and ...
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
(Date:6/24/2016)... ... 24, 2016 , ... SpiritQuest Sedona Retreats, located in Arizona has re-located to ... vortex sites: Cathedral Rock, Airport Mesa, and Boynton Canyon. The new retreat center ... as well as the Sedona Rouge, both popular accommodations for SpiritQuest clients. The ...
(Date:6/23/2016)... ... June 23, 2016 , ... An article published June 8 ... between head and neck cancer in individuals with unhealthy oral hygiene habits. The article ... on whether they had gum disease, brushed their teeth on a daily basis, wore ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
Breaking Medicine Technology: